CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤的新型免疫治疗：后 CAR-T 细胞时代
英文原题：Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
查看英文原题
Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性（R/R）弥漫大 B 细胞淋巴瘤（DLBCL）患者预后较差。以 CD19 嵌合抗原受体（CAR）T 细胞疗法为代表的免疫治疗已彻底改变 R/R DLBCL 治疗格局，可使约 50% 患者获得持久缓解。然而，CAR-T 细胞治疗后仍有患者无应答或复发，迫切需要开发新疗法改善其临床结局。缺乏合适免疫治疗靶点及疾病异质性是这一新兴领域的主要挑战。本文综述 CAR-T 时代后已获批及新兴的 R/R DLBCL 免疫疗法，并介绍目前使用的细胞表面靶点。
展开英文摘要原文
Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50% of patients.
However, there remains an unmet need for developing novel therapies to improve clinical outcomes of patients not responding or relapsing after CAR T cell therapies. Lack of suitable immunotherapeutic targets and disease heterogeneity represent the foremost challenges in this emerging field. In this review, we discuss the recently approved and emerging novel immunotherapies for patients with R/R DLBCL in the post-CAR T era and the cell surface targets currently used.
论文信息
- 作者
- Atallah-Yunes SA、Robertson MJ、Davé UP、Ghione P、Perna F
- 单位
- Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.Italy
- 文献类型
- 综述 · 美国政府（非公共卫生署）资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 35720352 · DOI 10.3389/fimmu.2022.901365
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →